Sangamo Therapeutics, Inc.SGMO was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 38.6% in the past one-month time frame.
The company has seen 2 negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Sangamo Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Sangamo Therapeutics, Inc. Price
Sangamo Therapeutics, Inc. Price | Sangamo Therapeutics, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Anika Therapeutics, Inc. ANIK , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is SGMO going up? Or down? Predict to see what others think: Up or Down
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAnika Therapeutics Inc. (ANIK): Free Stock Analysis ReportSangamo Therapeutics, Inc. (SGMO): Free Stock Analysis ReportTo read this article on Zacks.com click here.